
Improved survival in stroke patients

Your partner in VTE prevention





Clots 3 trial

- Randomised, controlled, blinded trial
- 2,876 hospitalised stroke patients
- Published in Lancet (May 2013)
- 105 centres within the United Kingdom

1,438
No IPC + Routine care

1,434 (99.72%)

Adhered to treatment allocation

12.1% (174)

Proximal DVT

2,876

Acute stroke patients, hospitalised & immobile

1,438

IPC + Routine care

1,424 (99.02%)

Adhered to treatment allocation

8.5% (122)

Proximal DVT

IPC = The Cardinal Health™ Kendall SCD™ system with vascular refill detection, sequential circumferential thigh length sleeves (provided and manufactured by Cardinal Health™)

Routine Care = May have included hydration, aspirin, graduated compression stockings, and/or anticoagulants

p = 0001

DVT = Deep Vein Thrombosis

PE = Pulmonary Embolism

IPC = Intermittent Pneumatic Compression

VTE = Venous Thromboembolism

Reference:

Dennis MS, et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (Clots 3): a multicentre randomised controlled trial. The Lancet. Published online: 31 May, 2013

IMPORTANT: Please refer to the package insert for complete instructions, contraindications, warnings and precautions

© 2018 Cardinal Health. All rights reserved.

CARDINAL HEALTH, Cardinal Health LOGO and KENDALL SCD are trademarks of Cardinal Health and may be registered in the US and/or in other countries. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. For healthcare professionals only. As part of its continuous product development policy, Cardinal Health reserves the right to change product specifications without prior notification. Please contact your Cardinal Health representative for additional product availability information.

Powerful results. Proven prevention.

29,9%

Proximal DVT reduction



14,0%

Mortality risk reduction

"At last we have a simple, effective and affordable treatment that reduces the risk of DVT and even appears to reduce the risk of dying after stroke."

Prof. Martin Dennis, Principal Investigator, Clots 3

